Almac Group Participates in GCSBWG

Published on: September 17, 2019

Applied Clinical Trials

Almac Group, the global contract pharmaceutical development and manufacturing organization, is pleased to announce its participation in the Global Clinical Supply BlockChain working group (GCSBWG).Other Clinical Supply Blockchain Working Group members are from Pfizer, Merck, UCLA, Bracket, Thermo Fisher, Barry Moore, GlaxoSmithKline, Marken, and GS1.

With Phase 1 of the GSCWG complete, the group has published a whitepaper entitled “Transforming Pharmaceutical Clinical Supply Messaging with BlockChain”which outlines the program’s highlights to date. An iOS mobile application called “KitChain MVP” has also been built upon a hyperleger fabric permissioned BlockChain infrastructure. The ultimate aim of the working group is to envision a messaging and notification platform which can support the performance requirements of the whole clinical supply chain.

Almac’s Mark Hanly, Strategic Business Analysis Manager and Mark McColgan, Software Development Manager, will continue to work alongside a diverse group of global academia, pharmaceutical companies and other Contract Manufacturing Organisations through the next phases of the working group and contribute pertinent insight and debate. With this group there was significant potential to enhance the depth and breadth of knowledge on how BlockChain could potentially be applied in the industry.

Andrew Hillis, Vice President and Group Head of Information Services, Almac Group, commented, “The rapid adoption of BlockChain technology, coupled with its clear applicability to the clinical supply chain, make this project extremely timely and relevant to meeting the future challenges of our industry. We’re privileged to contribute our experiences and perspectives as one of the world’s largest global clinical supply providers to this endeavor that if successful, will undoubtedly have a major impact on clinical sites and ultimately, patients.”